PDCD1 and myocarditis: Methylprednisolone has been shown to ameliorate the symptoms of myocarditis and acute heart failure induced by other PD-1 inhibitors, including camrelizumab, nivolumab, tislelizumab, and toripalimab (Monge et al., 2018; Fazel and Jedlowski, 2019; Bai et al., 2021; Hu et al., 2021; Jespersen et al., 2021; Komatsu et al., 2021; Luo et al., 2021; Wang et al., 2021; Zhang et al., 2022a).